

# Corona Onderzoek Limburg

Gepubliceerd: 10-09-2020 Laatste bijgewerkt: 18-08-2022

Certain determinants (risk exposure, symptoms, compliance with measures) can be identified to be associated with a positive SARS-CoV-2 antibody test in inhabitants of 18 years and older of the province of Limburg

|                             |                                                     |
|-----------------------------|-----------------------------------------------------|
| <b>Ethische beoordeling</b> | Positief advies                                     |
| <b>Status</b>               | Werving gestopt                                     |
| <b>Type aandoening</b>      | -                                                   |
| <b>Onderzoekstype</b>       | Observationeel onderzoek, zonder invasieve metingen |

## Samenvatting

### ID

NL-OMON26626

### Bron

NTR

### Verkorte titel

COL

### Aandoening

Sars-Cov-2-antibodies

## Ondersteuning

**Primaire sponsor:** GGD South Limburg

**Overige ondersteuning:** GGD South Limburg and Province of Limburg

## Onderzoeksproduct en/of interventie

## Uitkomstmaten

### Primaire uitkomstmaten

The primary outcome measure of the study is the result of SARS-CoV-2 antibody testing (positive or negative), based on total IgG (dichotomous value).

# Toelichting onderzoek

## Achtergrond van het onderzoek

**Rationale:** It is highly important to generate knowledge about the nature and determinants of the spread of SARS-CoV-2 in Limburg, a region severely affected by the COVID-19 pandemic. We hope to gain more insight into why Limburg has been severely affected by looking at possible risk exposure. The results of the study will, in addition to providing insight, contribute to the more targeted deployment of COVID-19 measures in 2020.

**Objective:** The primary objective of the study is to examine which determinants (risk exposure, symptoms, compliance with measures) are associated with a positive SARS-CoV-2 antibody test in inhabitants of the province of Limburg.

**Study design:** The study is a cross-sectional study with invasive measurements (blood-sampling by venepuncture).

**Study population:** Adult Limburgers (18 years and older) can participate in the study. The planned number of participants is 10.000.

**Main study parameters/endpoints:** The primary outcome measure of the study is the result of SARS-CoV-2 antibody testing (positive or negative), based on total IgG (dichotomous value). We study the association of a range of determinants with this outcome.

**Nature and extent of the burden and risks associated with participation, benefit and group relatedness:** This study is low risk.

The questionnaire is non-invasive, it costs some time to fill in (about 35-40 minutes).

The venepuncture is a minimum burden. It is being conducted by well-trained and qualified staff, under the responsibility of the GGD. The risk therefore is very small. The participants receive the result of the corona-antibody test.

## Doel van het onderzoek

Certain determinants (risk exposure, symptoms, compliance with measures) can be identified to be associated with a positive SARS-CoV-2 antibody test in inhabitants of 18 years and older of the province of Limburg

## Onderzoeksopzet

Cross-sectional (with option to be included in future follow-up measures)

## Onderzoeksproduct en/of interventie

No interventions; observational study

# Contactpersonen

## Publiek

GGD Zuid Limburg  
Nicole Dukers-Muijrs

+31(0)629193150

## Wetenschappelijk

GGD Zuid Limburg  
Nicole Dukers-Muijrs

+31(0)629193150

## Deelname eisen

### Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

18 years and older and residence in Limburg, Netherlands

### Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

younger than 18 years or no residence in Limburg

## Onderzoeksopzet

### Opzet

|                  |                                                     |
|------------------|-----------------------------------------------------|
| Type:            | Observationeel onderzoek, zonder invasieve metingen |
| Onderzoeksmodel: | Anders                                              |
| Toewijzing:      | N.v.t. / één studie arm                             |
| <b>Controle:</b> | N.v.t. / onbekend                                   |

### Deelname

Nederland

|                         |                       |
|-------------------------|-----------------------|
| Status:                 | Werving gestopt       |
| (Verwachte) startdatum: | 10-09-2020            |
| Aantal proefpersonen:   | 10000                 |
| Type:                   | Werkelijke startdatum |

## Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

**Wordt de data na het onderzoek gedeeld:** Nog niet bepaald

### Toelichting

Not yet available

## Ethische beoordeling

|                 |                  |
|-----------------|------------------|
| Positief advies |                  |
| Datum:          | 10-09-2020       |
| Soort:          | Eerste indiening |

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

### In overige registers

| Register       | ID                                                                               |
|----------------|----------------------------------------------------------------------------------|
| NTR-new        | NL8889                                                                           |
| Ander register | Approved Medical Ethical Committee of the University of Maastricht : METC 20-071 |

# Resultaten

## Samenvatting resultaten

Not yet available